Delivery Order SPE2DB20D1109-SPE2DB25FP66T
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,924.08 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pen injections on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed price contract, awarded without set-aside designation through competitive procurement, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,143.87 firm fixed-price delivery order on July 22, 2025, for Zepbound 15 mg/0.5 ml pen injections. This is a competitively awarded, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and an ultimate completion date of July 23, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $6,706.07. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 prime vendor agreement through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injections on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency awarded a $14,216.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen injections on July 30, 2025, with completion targeted for July 31, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a $1,003.39 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections with a completion date of August 4, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 billion through December 2026. AmerisourceBergen, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,669.05 on August 18, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award, and specifies performance completion by August 19, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,360.72 for Zepbound 7.5 mg/0.5 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The contract carries no set-aside designation and...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP66TDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $14,240.92 for Zepbound 5 mg/0.5 ml pen injections, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract does not utilize a set-aside designation, and performance will be conducted at the contractor's facility in Conshohocken, Pennsylvania. This delivery order exemplifies AmerisourceBergen's critical role as a pharmaceutical distributor within the federal medical supply chain, particularly for Defense Health Agency and military healthcare systems. As a major prime vendor under the DLA's comprehensive pharmaceutical support vehicle, AmerisourceBergen supplies a wide spectrum of medications and medical commodities to support military healthcare programs globally. Zepbound, a diabetes and weight management medication, represents one of many specialized pharmaceuticals the contractor delivers through its federal contract portfolio, demonstrating the company's capability to fulfill strategic medical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 8/29/25 |